160 related articles for article (PubMed ID: 4149420)
1. Interindividual differences in drug oxidation: clinical importance.
Sjöqvist F; von Bahr C
Drug Metab Dispos; 1973; 1(1):469-82. PubMed ID: 4149420
[No Abstract] [Full Text] [Related]
2. Interindividual differences in rates of drug oxidation in man.
Davies DS; Thorgeirsson SS; Breckenridge A; Orme M
Drug Metab Dispos; 1973; 1(1):411-7. PubMed ID: 4149412
[No Abstract] [Full Text] [Related]
3. Genetic factors in hepatic drug oxidation.
Kalow W; Inaba T
Prog Liver Dis; 1976; 5():246-58. PubMed ID: 775542
[No Abstract] [Full Text] [Related]
4. Interindividual differences in pharmacokinetics in man: clinical importance.
Sjöqvist F
Panminerva Med; 1973 Apr; 15(4):99-112. PubMed ID: 4808047
[No Abstract] [Full Text] [Related]
5. Editorial: Drug metabolism in disease.
Lancet; 1974 Apr; 1(7861):790-1. PubMed ID: 4132718
[No Abstract] [Full Text] [Related]
6. Individual differences in the disposition of drugs metabolised in the body.
Alvan G
Clin Pharmacokinet; 1978; 3(2):155-75. PubMed ID: 346288
[No Abstract] [Full Text] [Related]
7. [Inter-individual differences in pharmacokinetics in humans: clinical importance].
Sjöqvist F
Minerva Med; 1973 Mar; 64(17):866-79. PubMed ID: 4703858
[No Abstract] [Full Text] [Related]
8. Drug metabolism in uremia.
Reidenberg MM
Clin Nephrol; 1975; 4(3):83-5. PubMed ID: 1102176
[No Abstract] [Full Text] [Related]
9. Antipyrine half-life and drug elimination.
Breckenridge A
Clin Pharmacokinet; 1980; 5(3):201-3. PubMed ID: 7389234
[No Abstract] [Full Text] [Related]
10. Sensible prescribing. II--What happens to all the pills they swallow?
Rawlins MD
Practitioner; 1975 Feb; 214(1280):274-81. PubMed ID: 1144254
[No Abstract] [Full Text] [Related]
11. Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity.
Soda DM; Levy G
J Pharm Sci; 1975 Dec; 64(12):1928-31. PubMed ID: 1206483
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent effect of propafenone on in vivo drug metabolism in the rat.
Chong MT; Svensson CK
Res Commun Chem Pathol Pharmacol; 1987 Nov; 58(2):147-56. PubMed ID: 3423421
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of drug metabolism in man.
Vesell ES; Passananti GT
Drug Metab Dispos; 1973; 1(1):402-10. PubMed ID: 4129869
[No Abstract] [Full Text] [Related]
14. Impairment of drug metabolism in man by allopurinol and nortriptyline.
Vesell ES; Passananti GT; Greene FE
N Engl J Med; 1970 Dec; 283(27):1484-8. PubMed ID: 4098480
[No Abstract] [Full Text] [Related]
15. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].
Idle JR; Sloan TP; Smith RL; Wakile LA
Br J Pharmacol; 1979 Jul; 66(3):430P-431P. PubMed ID: 526719
[No Abstract] [Full Text] [Related]
16. Proceedings: Structural effects in pharmacokinetics and drug response.
Notari RE
Acta Pharm Suec; 1974 Dec; 11(6):633-5. PubMed ID: 1136785
[No Abstract] [Full Text] [Related]
17. Interindividual differences in the metabolism of xenobiotics.
Conney AH; Kappas A
Carcinog Compr Surv; 1985; 10():147-66. PubMed ID: 3933828
[TBL] [Abstract][Full Text] [Related]
18. [Differences between individuals in human pharmacokinetics. Clinical significance].
Sjöqvist F
Munch Med Wochenschr; 1972 Sep; 114(38):1600-8. PubMed ID: 4678410
[No Abstract] [Full Text] [Related]
19. Cytochrome P-450 and drug oxidation.
Davies DS
Biochem J; 1969 Dec; 115(5):23P-24P. PubMed ID: 4391248
[No Abstract] [Full Text] [Related]
20. [Some fundamental concepts of pharmacokinetic practice].
Perrier CV; Griessen M
Pharm Acta Helv; 1974; 49(7-8):217-28. PubMed ID: 4462123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
